ReviewIndian journal of ophthalmology2018
Management of chronic central serous chorioretinopathy.
Review in Indian journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Efficacy and safety of 577 nm subthreshold laser treatment in acute central serous chorioretinopathy.BMC ophthalmology · 2026Article
- Sleep and mood in central serous chorioretinopathy.Eye (London, England) · 2025Article
- Oscillatory photodynamic therapy in central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Visual and anatomical evaluation of navigated subthreshold micropulse laser versus photodynamic therapy in managing chronic central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Gender differences in central serous chorioretinopathy based on the new multimodal imaging classification.Eye (London, England) · 2024Observational
- Randomized controlled trials in central serous chorioretinopathy: A review.Eye (London, England) · 2023Review
- Exploring New Therapeutic Avenues for Ophthalmic Disorders: Glaucoma-Related Molecular Docking Evaluation and Bibliometric Analysis for Improved Management of Ocular Diseases.Bioengineering (Basel, Switzerland) · 2023Article
- Efficacy and safety of subthreshold micropulse laser in the treatment of acute central serous chorioretinopathy.International journal of ophthalmology · 2023Article
- Morphometric analyses in patients treated with subthreshold laser photocoagulation for central serous chorioretinopathy.BMC ophthalmology · 2022Article
- Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities.Acta ophthalmologica · 2022Article
- Pregabalin as a probable cause of central serous chorioretinopathy: Two case reports.Turkish journal of physical medicine and rehabilitation · 2021Article
- Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Retinal neovascularization in a patient with chronic central serous chorioretinopathy.Indian journal of ophthalmology · 2020Article
- Commentary: Our understanding of central serous chorioretinopathy-coming a full circle?Indian journal of ophthalmology · 2020Article
- Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy.Journal of current ophthalmology · 2019Article
- Commentary: Management of central serous chorioretinopathy: Looking beyond the eye.Indian journal of ophthalmology · 2018Article
- Pachychoroid Spectrum Disorders: An Updated Review.Journal of ophthalmic & vision researchReview
- Focal Laser Photocoagulation for Central Serous Chorioretinopathy in Under-Represented Populations: A Retrospective Case Series.Case reports in ophthalmologyArticle
- Retrospective Large Database Study of Central Serous Chorioretinopathy Treatments and Visual Outcomes Analysis in the United States.Journal of vitreoretinal diseasesArticle
- Bilateral multifocal and recurrent chorioretinopathy - case report.Romanian journal of ophthalmologyArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New treatment modalities for the management of central serous chorioretinopathy (CSC) now exist. While acute CSC generally resolves without the requirement for intervention, chronic CSC has been associated with persistent disruption in visual function. Current treatment approaches include photodynamic therapy, oral aldosterone antagonism and subthreshold multifocal laser. There has also been further investigation into a number of new treatments including antivascular endothelial growth factor treatment. Further investigation using developing optical coherence tomography imaging is helping to determine biomarkers of CSC activity, potential indicators of treatment response and indications of chronicity of disease activity. Further comparative study is required to determine the effectiveness of different forms of treatment in a range of patients with varied demographics, aetiology and chronicity of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.